1887

Chapter 16 : Immune Responses to Viral Infection

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Ebook: Choose a downloadable PDF or ePub file. Chapter is a downloadable PDF file. File must be downloaded within 48 hours of purchase

Buy this Chapter
Digital (?) $30.00

Preview this chapter:
Zoom in
Zoomout

Immune Responses to Viral Infection, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555819439/9781555819422.ch16-1.gif /docserver/preview/fulltext/10.1128/9781555819439/9781555819422.ch16-2.gif

Abstract:

The concept of “immunity” dates back to ancient Greece, where as early as the fifth century BC, documented cases of “immune” individuals were described who were related to individuals who recovered from the plague (1). However, it was not until the 10th century that specific “interventions” were described that could induce immunity. In both China and the Middle East, a process known as “variolation,” consisting of purposefully exposing healthy individuals to the contents of dried variola lesions, was actively practiced to prevent severe infection with smallpox. In the early 18 century, the practice of variolation was brought to Great Britain, where the development of the first vaccine by Jenner catalyzed the creation of the field of immunology. Beginning in the late 19 century, major breakthroughs, including the establishment of the “germ theory” by Koch and Pasteur, which held that disease was caused by bacteria or pathogens; the discovery of phagocytic cells by Metchnikoff; the identification of immune proteins in serum by von Behring and Kitasato; the identification of B cells and their regulation by Ehrlich; the discovery of lymphocytes by Gowan; the identification of pattern recognition receptors and innate immune activity by Janeway; and the discovery of dendritic cells, which link the innate and adaptive immune system, by Steinman, collectively gave rise to modern immunology and our current appreciation for the host immune response. This response has evolved to contain, eliminate, and remember virtually any pathogen to which it is exposed. This chapter reviews the components of the immune system, focusing on the innate and adaptive immune response to viral infection and how these arms of the immune system collaborate to prevent and control viral disease.

Citation: Streeck H, Suscovich T, Alter G. 2017. Immune Responses to Viral Infection, p 321-350. In Richman D, Whitley R, Hayden F (ed), Clinical Virology, Fourth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555819439.ch16
Highlighted Text: Show | Hide
Loading full text...

Full text loading...

Figures

Image of FIGURE 1
FIGURE 1

Three layers of immunity: physical barrier immunity, innate immunity, and adaptive immunity. 1) Physical barriers, including the skin and mucosal membranes, represent the first level of protection against foreign invaders. Damage to this layer can lead to pathogen access to the underlying cells. Many viruses utilize vectors to breach this barrier. 2) Innate immunity represents the nonspecific rapid response arm of the immune system, and the first white blood cell responders help control, clear, and arm the immune response. C) Adaptive immunity consists of the antigen-specific response that evolves to specifically clear the pathogen and to confer long-lived immunity against the pathogen upon re-exposure.

Citation: Streeck H, Suscovich T, Alter G. 2017. Immune Responses to Viral Infection, p 321-350. In Richman D, Whitley R, Hayden F (ed), Clinical Virology, Fourth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555819439.ch16
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 2
FIGURE 2

The two arms of the immune system. All immune cells develop from a common hematopoietic stem-cell progenitor that can differentiate into a myeloid or common lymphoid progenitor (CLP). The adaptive arm of the immune system is composed of four immune cell types, called lymphocytes, that share a CLP origin. The innate arm consists of an array of distinct cell types, most of which are derived from the myeloid progenitor, except NK cells and plasmacytoid dendritic cells that differentiate from a CLP.

Citation: Streeck H, Suscovich T, Alter G. 2017. Immune Responses to Viral Infection, p 321-350. In Richman D, Whitley R, Hayden F (ed), Clinical Virology, Fourth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555819439.ch16
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 3
FIGURE 3

Innate immune receptors. Four types of pattern recognition receptors exist that drive a rapid response to foreign pathogens including 1) extracellular secreted receptors such as mannose-binding lectin, 2) cell surface toll-like receptors or c-type lectin receptors, 3) endosomal TLRs, and 4) cytosolic pattern recognition receptors such as RigI. The secreted and surface-bound PRRs recognize extracellular pathogens whereas the endosomal and cytosolic PRRs recognize pathogens that have entered into different cellular compartments within the cell.

Citation: Streeck H, Suscovich T, Alter G. 2017. Immune Responses to Viral Infection, p 321-350. In Richman D, Whitley R, Hayden F (ed), Clinical Virology, Fourth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555819439.ch16
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 4
FIGURE 4

Comparison of the structure of the major histocompatibility complexes (MHC) I and II. While class I molecules are composed of a polymorphic α chain noncovalently attached to the nonpolymorphic β2 microglobulin, class II are composed of a polymorphic α chain noncovalently attached to a polymorphic β2 microglobulin. While the peptide binding cleft of MHC I is closed, allowing only little sequence variation, the binding groove of MHC class II is open, even allowing tertiary structures.

Citation: Streeck H, Suscovich T, Alter G. 2017. Immune Responses to Viral Infection, p 321-350. In Richman D, Whitley R, Hayden F (ed), Clinical Virology, Fourth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555819439.ch16
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 5
FIGURE 5

CD4 T-cell subsets. The various functional CD4 T-cell subsets are depicted, their associated main transcription factors, the cytokines they secrete, and their main effector functions.

Citation: Streeck H, Suscovich T, Alter G. 2017. Immune Responses to Viral Infection, p 321-350. In Richman D, Whitley R, Hayden F (ed), Clinical Virology, Fourth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555819439.ch16
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 6
FIGURE 6

The IgH locus. The human immunoglobulin locus consists of two regions that give rise to either 1) the variable domain (Fab) or the 2) the crystallizable/constant domain (Fc). The Fab is generated following the rearrangement and selection of a V, a D, and a J segment that are assembled and tethered to the Fc region, which is also selected following gene rearrangement and selection of a single constant gene segment. Gene rearrangement requires the cutting out of excess DNA and religation of DNA ends, generating irreversible changes in the IgH locus.

Citation: Streeck H, Suscovich T, Alter G. 2017. Immune Responses to Viral Infection, p 321-350. In Richman D, Whitley R, Hayden F (ed), Clinical Virology, Fourth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555819439.ch16
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 7
FIGURE 7

The germinal center reaction. The germinal center reaction begins with an initial contact between B cells and cognate Tfh cells through an array of different receptors such as PD1-PDL1, CD40-CD40L, ICOS-ICOS-L, and TCR-MHCII. This promotes extensive proliferation of antigen-primed B cells. The GC cycle is thought to form two microanatomically distinct regions: the T-cell zone-proximal dark zone (which contains proliferating centroblasts) and the T-cell zone-distal light zone (which contains centrocytes, follicular dendritic cell [DC] networks and antigen-specific gcTFH cells). The expansion of antigen-specific B cells in the dark zone is accompanied by B-cell receptor (BCR) diversification through somatic hypermutation and class switch recombination. Loss of binding through this process leads to apoptosis, and only the best “binders” receive positive signals and enter the cycle again until they leave the GC as plasmablasts or memory B cells.

Citation: Streeck H, Suscovich T, Alter G. 2017. Immune Responses to Viral Infection, p 321-350. In Richman D, Whitley R, Hayden F (ed), Clinical Virology, Fourth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555819439.ch16
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 8
FIGURE 8

Distinct Fc-receptor expression profiles on distinct innate immune cells. Differences in Fc receptor expression profiles on distinct innate immune cell subsets enable these cells to respond to antibody-opsonized material differently to promote control and clearance of pathogens. Specifically, while NK cells and neutrophils largely express a single Fcγ-receptor, FcγR3a, on NK cells and FcγR3b on neutrophils, macrophages express nearly all Fc receptors including the two activating FcγR2a and FcγR3a receptors, as well as the sole inhibitory FcγR2b receptor.

Citation: Streeck H, Suscovich T, Alter G. 2017. Immune Responses to Viral Infection, p 321-350. In Richman D, Whitley R, Hayden F (ed), Clinical Virology, Fourth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555819439.ch16
Permissions and Reprints Request Permissions
Download as Powerpoint

References

/content/book/10.1128/9781555819439.ch16
1. Greenberg S. A Concise History of Immunology.
2. Cadwell K. 2015. The virome in host health and disease. Immunity 42:805813.[PubMed]
3. Wylie KM, Weinstock GM, Storch GA. 2012. Emerging view of the human virome. Transl Res 160:283290.[PubMed]
4. Pasparakis M, Haase I, Nestle FO. 2014. Mechanisms regulating skin immunity and inflammation. Nat Rev Immunol 14:289301.[PubMed]
5. Relan M, Lehman HK. 2014. Common dermatologic manifestations of primary immune deficiencies. Curr Allergy Asthma Rep 14:480.[PubMed]
6. Merad M, Ginhoux F, Collin M. 2008. Origin, homeostasis and function of Langerhans cells and other langerin-expressing dendritic cells. Nat Rev Immunol 8:935947.[PubMed]
7. Belkaid Y, Artis D. 2013. Immunity at the barriers. Eur J Immunol 43:30963097.[PubMed]
8. Fahy JV, Dickey BF. 2010. Airway mucus function and dysfunction. N Engl J Med 363:22332247.[PubMed]
9. Kesimer M, Ehre C, Burns KA, Davis CW, Sheehan JK, Pickles RJ. 2013. Molecular organization of the mucins and glycocalyx underlying mucus transport over mucosal surfaces of the airways. Mucosal Immunol 6:379392.[PubMed]
10. Haridas D, Ponnusamy MP, Chugh S, Lakshmanan I, Seshacharyulu P, Batra SK. 2014. MUC16: molecular analysis and its functional implications in benign and malignant conditions. FASEB J 28:41834199.[PubMed]
11. Belkaid Y, Segre JA. 2014. Dialogue between skin microbiota and immunity. Science 346:954959.[PubMed]
12. Kau AL, Ahern PP, Griffin NW, Goodman AL, Gordon JI. 2011. Human nutrition, the gut microbiome and the immune system. Nature 474:327336.[PubMed]
13. Gao Z, Kang Y, Yu J, Ren L. 2014. Human pharyngeal microbiome may play a protective role in respiratory tract infections. Genomics Proteomics Bioinformatics 12:144150.[PubMed]
14. d'Ettorre G, Ceccarelli G, Giustini N, Serafino S, Calantone N, De Girolamo G, Bianchi L, Bellelli V, Ascoli-Bartoli T, Marcellini S, Turriziani O, Brenchley JM, Vullo V. 2015. Probiotics reduce inflammation in antiretroviral treated, HIV-infected individuals: results of the “Probio-HIV” clinical trial. PLoS One 10:e0137200.[PubMed]
15. Ichinohe T, Pang IK, Kumamoto Y, Peaper DR, Ho JH, Murray TS, Iwasaki A. 2011. Microbiota regulates immune defense against respiratory tract influenza A virus infection. Proc Natl Acad Sci USA 108:53545359.[PubMed]
16. Anahtar MN, Byrne EH, Doherty KE, Bowman BA, Yamamoto HS, Soumillon M, Padavattan N, Ismail N, Moodley A, Sabatini ME, Ghebremichael MS, Nusbaum C, Huttenhower C, Virgin HW, Ndung'u T, Dong KL, Walker BD, Fichorova RN, Kwon DS. 2015. Cervicovaginal bacteria are a major modulator of host inflammatory responses in the female genital tract. Immunity 42:965976.[PubMed]
17. Williams SC. 2013. The other microbiome. Proc Natl Acad Sci USA 110:26822684.[PubMed]
18. Monaco CL, Gootenberg DB, Zhao G, Handley SA, Ghebremichael MS, Lim ES, Lankowski A, Baldridge MT, Wilen CB, Flagg M, Norman JM, Keller BC, Luévano JM, Wang D, Boum Y, Martin JN, Hunt PW, Bangsberg DR, Siedner MJ, Kwon DS, Virgin HW. 2016. Altered virome and bacterial microbiome in human immunodeficiency virus-associated acquired immunodeficiency syndrome. Cell Host Microbe 19:311322.[PubMed]
19. Ginhoux F, Jung S. 2014. Monocytes and macrophages: developmental pathways and tissue homeostasis. Nat Rev Immunol 14:392404.[PubMed]
20. Mercer J, Greber UF. 2013. Virus interactions with endocytic pathways in macrophages and dendritic cells. Trends Microbiol 21:380388.[PubMed]
21. Abbas W, Tariq M, Iqbal M, Kumar A, Herbein G. 2015. Eradication of HIV-1 from the macrophage reservoir: an uncertain goal? Viruses 7:15781598.[PubMed]
22. Amulic B, Cazalet C, Hayes GL, Metzler KD, Zychlinsky A. 2012. Neutrophil function: from mechanisms to disease. Annu Rev Immunol 30:459489.[PubMed]
23. Jenne CN, Wong CH, Zemp FJ, McDonald B, Rahman MM, Forsyth PA, McFadden G, Kubes P. 2013. Neutrophils recruited to sites of infection protect from virus challenge by releasing neutrophil extracellular traps. Cell Host Microbe 13:169180.[PubMed]
24. Drescher B, Bai F. 2013. Neutrophil in viral infections, friend or foe? Virus Res 171:17.[PubMed]
25. Tate MD, Ioannidis LJ, Croker B, Brown LE, Brooks AG, Reading PC. 2011. The role of neutrophils during mild and severe influenza virus infections of mice. PLoS One 6:e17618.[PubMed]
26. Cole ET, Rees JE, Hersey JA. 1971. Preliminary compaction studies using a device to simulate a rotary tabletting machine. J Pharm Pharmacol 23(S1):258S.[PubMed]
27. Hampton HR, Bailey J, Tomura M, Brink R, Chtanova T. 2015. Microbe-dependent lymphatic migration of neutrophils modulates lymphocyte proliferation in lymph nodes. Nat Commun 6:7139.[PubMed]
28. Slifman NR, Loegering DA, McKean DJ, Gleich GJ. 1986. Ribonuclease activity associated with human eosinophil-derived neurotoxin and eosinophil cationic protein. J Immunol 137:29132917.[PubMed]
29. Rosenberg HF, Dyer KD, Foster PS. 2013. Eosinophils: changing perspectives in health and disease. Nat Rev Immunol 13:922.[PubMed]
30. Diebold SS, Kaisho T, Hemmi H, Akira S, Reis e Sousa C. 2004. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 303:15291531.[PubMed]
31. Garofalo R, Kimpen JL, Welliver RC, Ogra PL. 1992. Eosinophil degranulation in the respiratory tract during naturally acquired respiratory syncytial virus infection. J Pediatr 120:2832.[PubMed]
32. Chakraborty NG, Twardzik DR, Sivanandham M, Ergin MT, Hellstrom KE, Mukherji B. 1990. Autologous melanoma-induced activation of regulatory T cells that suppress cytotoxic response. J Immunol 145:23592364.[PubMed]
33. Moore ML, Newcomb DC, Parekh VV, Van Kaer L, Collins RD, Zhou W, Goleniewska K, Chi MH, Mitchell D, Boyce JA, Durbin JE, Sturkie C, Peebles RS Jr. 2009. STAT1 negatively regulates lung basophil IL-4 expression induced by respiratory syncytial virus infection. J Immunol 183:20162026.[PubMed]
34. Kim BS, Wang K, Siracusa MC, Saenz SA, Brestoff JR, Monticelli LA, Noti M, Tait Wojno ED, Fung TC, Kubo M, Artis D. 2014. Basophils promote innate lymphoid cell responses in inflamed skin. J Immunol 193:37173725.[PubMed]
35. Leyva-Castillo JM, Hener P, Michea P, Karasuyama H, Chan S, Soumelis V, Li M. 2013. Skin thymic stromal lymphopoietin initiates Th2 responses through an orchestrated immune cascade. Nat Commun 4:2847.[PubMed]
36. Nakashima C, Otsuka A, Kitoh A, Honda T, Egawa G, Nakajima S, Nakamizo S, Arita M, Kubo M, Miyachi Y, Kabashima K. 2014. Basophils regulate the recruitment of eosinophils in a murine model of irritant contact dermatitis. J Allergy Clin Immunol 134:100107.[PubMed]
37. Turkewitz LJ, Levin M. 1988. Acute inflammation of the temporomandibular joint presenting as classical trigeminal neuralgia—case report and hypothesis. Headache 28:2425.[PubMed]
38. von Köckritz-Blickwede M, Goldmann O, Thulin P, Heinemann K, Norrby-Teglund A, Rohde M, Medina E. 2008. Phagocytosis-independent antimicrobial activity of mast cells by means of extracellular trap formation. Blood 111:30703080.[PubMed]
39. Artis D, Spits H. 2015. The biology of innate lymphoid cells. Nature 517:293301.[PubMed]
40. Cerwenka A, Lanier LL. 2001. Natural killer cells, viruses and cancer. Nat Rev Immunol 1:4149.[PubMed]
41. Orange JS. 2012. Unraveling human natural killer cell deficiency. J Clin Invest 122:798801.[PubMed]
42. Khakoo SI, Thio CL, Martin MP, Brooks CR, Gao X, Astemborski J, Cheng J, Goedert JJ, Vlahov D, Hilgartner M, Cox S, Little AM, Alexander GJ, Cramp ME, O'Brien SJ, Rosenberg WM, Thomas DL, Carrington M. 2004. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science 305:872874.[PubMed]
43. Martin MP, Gao X, Lee JH, Nelson GW, Detels R, Goedert JJ, Buchbinder S, Hoots K, Vlahov D, Trowsdale J, Wilson M, O'Brien SJ, Carrington M. 2002. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat Genet 31:429434.[PubMed]
44. Piguet V, Schwartz O, Le Gall S, Trono D. 1999. The downregulation of CD4 and MHC-I by primate lentiviruses: a paradigm for the modulation of cell surface receptors. Immunol Rev 168:5163.[PubMed]
45. Benz C, Reusch U, Muranyi W, Brune W, Atalay R, Hengel H. 2001. Efficient downregulation of major histocompatibility complex class I molecules in human epithelial cells infected with cytomegalovirus. J Gen Virol 82:20612070.[PubMed]
46. Saunders PM, Vivian JP, O'Connor GM, Sullivan LC, Pymm P, Rossjohn J, Brooks AG. 2015. A bird's eye view of NK cell receptor interactions with their MHC class I ligands. Immunol Rev 267:148166.[PubMed]
47. Cerwenka A, Lanier LL. 2003. NKG2D ligands: unconventional MHC class I-like molecules exploited by viruses and cancer. Tissue Antigens 61:335343.[PubMed]
48. Mandelboim O, Lieberman N, Lev M, Paul L, Arnon TI, Bushkin Y, Davis DM, Strominger JL, Yewdell JW, Porgador A. 2001. Recognition of haemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells. Nature 409:10551060.[PubMed]
49. Horowitz A, Strauss-Albee DM, Leipold M, Kubo J, Nemat-Gorgani N, Dogan OC, Dekker CL, Mackey S, Maecker H, Swan GE, Davis MM, Norman PJ, Guethlein LA, Desai M, Parham P, Blish CA. 2013. Genetic and environmental determinants of human NK cell diversity revealed by mass cytometry. Sci Transl Med 5:208ra145.[PubMed]
50. Sun JC, Lopez-Verges S, Kim CC, DeRisi JL, Lanier LL. 2011. NK cells and immune “memory.” J Immunol 186:18911897.[PubMed]
51. Paust S, von Andrian UH. 2011. Natural killer cell memory. Nat Immunol 12:500508.[PubMed]
52. Reeves RK, Li H, Jost S, Blass E, Li H, Schafer JL, Varner V, Manickam C, Eslamizar L, Altfeld M, von Andrian UH, Barouch DH. 2015. Antigen-specific NK cell memory in rhesus macaques. Nat Immunol 16:927932.[PubMed]
53. Merad M, Sathe P, Helft J, Miller J, Mortha A. 2013. The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting. Annu Rev Immunol 31:563604.[PubMed]
54. Mildner A, Jung S. 2014. Development and function of dendritic cell subsets. Immunity 40:642656.[PubMed]
55. Adiko AC, Babdor J, Gutiérrez-Martínez E, Guermonprez P, Saveanu L. 2015. Intracellular transport routes for MHC I and their relevance for antigen cross-presentation. Front Immunol 6:335.[PubMed]
56. Dalod M, Chelbi R, Malissen B, Lawrence T. 2014. Dendritic cell maturation: functional specialization through signaling specificity and transcriptional programming. EMBO J 33:11041116.[PubMed]
57. Rowley DA, Fitch FW. 2012. The road to the discovery of dendritic cells, a tribute to Ralph Steinman. Cell Immunol 273:9598.[PubMed]
58. Schmid MA, Diamond MS, Harris E. 2014. Dendritic cells in dengue virus infection: targets of virus replication and mediators of immunity. Front Immunol 5:647.[PubMed]
59. Takeo K, de Hoog GS. 1991. Karyology and hyphal characters as taxonomic criteria in ascomycetous black yeasts and related fungi. Antonie van Leeuwenhoek 60:3542.[PubMed]
60. Bray M, Geisbert TW. 2005. Ebola virus: the role of macrophages and dendritic cells in the pathogenesis of Ebola hemorrhagic fever. Int J Biochem Cell Biol 37:15601566.[PubMed]
61. Kamp W, Berk MB, Visser CJ, Nottet HS. 2000. Mechanisms of HIV-1 to escape from the host immune surveillance. Eur J Clin Invest 30:740746.[PubMed]
62. McKenna K, Beignon AS, Bhardwaj N. 2005. Plasmacytoid dendritic cells: linking innate and adaptive immunity. J Virol 79:1727.[PubMed]
63. Pichyangkul S, Endy TP, Kalayanarooj S, Nisalak A, Yongvanitchit K, Green S, Rothman AL, Ennis FA, Libraty DH. 2003. A blunted blood plasmacytoid dendritic cell response to an acute systemic viral infection is associated with increased disease severity. J Immunol 171:55715578.[PubMed]
64. Chehimi J, Campbell DE, Azzoni L, Bacheller D, Papasavvas E, Jerandi G, Mounzer K, Kostman J, Trinchieri G, Montaner LJ. 2002. Persistent decreases in blood plasmacytoid dendritic cell number and function despite effective highly active antiretroviral therapy and increased blood myeloid dendritic cells in HIV-infected individuals. J Immunol 168:47964801.[PubMed]
65. Holers VM. 2014. Complement and its receptors: new insights into human disease. Annu Rev Immunol 32:433459.[PubMed]
66. Belpomme D, Cour V, Gisselbrecht C, Le Rol A, Mignot L, Marty M, Godeffroy W, Maral J. 1987. [Prolonged remissions induced by the combination vindesine, mitoxantrone, mitomycine C in metastatic breast cancers]. Presse Med 16:635.[PubMed]
67. Sprinzl M, Hartmann T, Meissner F, Moll J, Vorderwülbecke T. 1987. Compilation of tRNA sequences and sequences of tRNA genes. Nucleic Acids Res 15(Suppl):r53r188.[PubMed]
68. Stoiber H, Clivio A, Dierich MP. 1997. Role of complement in HIV infection. Annu Rev Immunol 15:649674.[PubMed]
69. O'Neill LA, Golenbock D, Bowie AG. 2013. The history of Toll-like receptors—redefining innate immunity. Nat Rev Immunol 13:453460.[PubMed]
70. Akira S, Takeda K. 2004. Toll-like receptor signalling. Nat Rev Immunol 4:499511.[PubMed]
71. Geijtenbeek TB, Gringhuis SI. 2009. Signalling through C-type lectin receptors: shaping immune responses. Nat Rev Immunol 9:465479.[PubMed]
72. Dube DH, Bertozzi CR. 2005. Glycans in cancer and inflammation—potential for therapeutics and diagnostics. Nat Rev Drug Discov 4:477488.[PubMed]
73. Ip WK, Takahashi K, Ezekowitz RA, Stuart LM. 2009. Mannose-binding lectin and innate immunity. Immunol Rev 230:921.[PubMed]
74. Zhang H, Zhou G, Zhi L, Yang H, Zhai Y, Dong X, Zhang X, Gao X, Zhu Y, He F. 2005. Association between mannose-binding lectin gene polymorphisms and susceptibility to severe acute respiratory syndrome coronavirus infection. J Infect Dis 192:13551361.[PubMed]
75. Ip WK, Chan KH, Law HK, Tso GH, Kong EK, Wong WH, To YF, Yung RW, Chow EY, Au KL, Chan EY, Lim W, Jensenius JC, Turner MW, Peiris JS, Lau YL. 2005. Mannose-binding lectin in severe acute respiratory syndrome coronavirus infection. J Infect Dis 191:16971704.[PubMed]
76. Hu J, Liu J, Yang D, Lu M, Yin J. 2014. Physiological roles of asialoglycoprotein receptors (ASGPRs) variants and recent advances in hepatic-targeted delivery of therapeutic molecules via ASGPRs. Protein Pept Lett 21:10251030.[PubMed]
77. Philpott DJ, Sorbara MT, Robertson SJ, Croitoru K, Girardin SE. 2014. NOD proteins: regulators of inflammation in health and disease. Nat Rev Immunol 14:923.[PubMed]
78. Jacobs SR, Damania B. 2012. NLRs, inflammasomes, and viral infection. J Leukoc Biol 92:469477.[PubMed]
79. Loo YM, Gale M Jr. 2011. Immune signaling by RIG-I-like receptors. Immunity 34:680692.[PubMed]
80. Ramos HJ, Gale M Jr. 2011. RIG-I like receptors and their signaling crosstalk in the regulation of antiviral immunity. Curr Opin Virol 1:167176.[PubMed]
81. Dinarello CA. 2007. Historical insights into cytokines. Eur J Immunol 37(Suppl 1):S34S45.[PubMed]
82. Schneider WM, Chevillotte MD, Rice CM. 2014. Interferon-stimulated genes: a complex web of host defenses. Annu Rev Immunol 32:513545.[PubMed]
83. Platanias LC. 2005. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol 5:375386.[PubMed]
84. McNab F, Mayer-Barber K, Sher A, Wack A, O'Garra A. 2015. Type I interferons in infectious disease. Nat Rev Immunol 15:87103.[PubMed]
85. Ozato K, Shin DM, Chang TH, Morse HC III. 2008. TRIM family proteins and their emerging roles in innate immunity. Nat Rev Immunol 8:849860.[PubMed]
86. Cullen BR. 2006. Role and mechanism of action of the APOBEC3 family of antiretroviral resistance factors. J Virol 80:10671076.[PubMed]
87. Kuhl BD, Cheng V, Wainberg MA, Liang C. 2011. Tetherin and its viral antagonists. J Neuroimmune Pharmacol 6:188201.[PubMed]
88. Neil SJ, Zang T, Bieniasz PD. 2008. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 451:425430.[PubMed]
89. Sakuma T, Noda T, Urata S, Kawaoka Y, Yasuda J. 2009. Inhibition of Lassa and Marburg virus production by tetherin. J Virol 83:23822385.[PubMed]
90. Schroder K, Hertzog PJ, Ravasi T, Hume DA. 2004. Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol 75:163189.[PubMed]
91. Donnelly RP, Kotenko SV. 2010. Interferon-lambda: a new addition to an old family. J Interferon Cytokine Res 30:555564.[PubMed]
92. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB. 2009. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461:399401.[PubMed]
93. Dinarello CA. 2004. Infection, fever, and exogenous and endogenous pyrogens: some concepts have changed. J Endotoxin Res 10:201222.[PubMed]
94. Stacey AR, Norris PJ, Qin L, Haygreen EA, Taylor E, Heitman J, Lebedeva M, DeCamp A, Li D, Grove D, Self SG, Borrow P. 2009. Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections. J Virol 83:37193733.[PubMed]
95. Comerford I, McColl SR. 2011. Mini-review series: focus on chemokines. Immunol Cell Biol 89:183184.[PubMed]
96. Griffith JW, Sokol CL, Luster AD. 2014. Chemokines and chemokine receptors: positioning cells for host defense and immunity. Annu Rev Immunol 32:659702.[PubMed]
97. Anderson G, Moore NC, Owen JJ, Jenkinson EJ. 1996. Cellular interactions in thymocyte development. Ann Rev Immunol 14:7399.[PubMed]
98. Carlyle JR, Zúñiga-Pflücker JC. 1998. Requirement for the thymus in alphabeta T lymphocyte lineage commitment. Immunity 9:187197.[PubMed]
99. Borowski C, Martin C, Gounari F, Haughn L, Aifantis I, Grassi F, von Boehmer H. 2002. On the brink of becoming a T cell. Curr Opin Immunol 14:200206.[PubMed]
100. Hayes SM, Love PE. 2002. Distinct structure and signaling potential of the gamma delta TCR complex. Immunity 16:827838.[PubMed]
101. Dudley EC, Petrie HT, Shah LM, Owen MJ, Hayday AC. 1994. T cell receptor beta chain gene rearrangement and selection during thymocyte development in adult mice. Immunity 1:8393.[PubMed]
102. Borowski C, Li X, Aifantis I, Gounari F, von Boehmer H. 2004. Pre-TCR alpha and TCR alpha are not interchangeable partners of TCR beta during T lymphocyte development. J Exp Med 199:607615.[PubMed]
103. Surh CD, Sprent J. 1994. T-cell apoptosis detected in situ during positive and negative selection in the thymus. Nature 372:100103.[PubMed]
104. Huesmann M, Scott B, Kisielow P, von Boehmer H. 1991. Kinetics and efficacy of positive selection in the thymus of normal and T cell receptor transgenic mice. Cell 66:533540.[PubMed]
105. Zerrahn J, Held W, Raulet DH. 1997. The MHC reactivity of the T cell repertoire prior to positive and negative selection. Cell 88:627636.[PubMed]
106. He X, He X, Dave VP, Zhang Y, Hua X, Nicolas E, Xu W, Roe BA, Kappes DJ. 2005. The zinc finger transcription factor Th-POK regulates CD4 versus CD8 T-cell lineage commitment. Nature 433:826833.[PubMed]
107. Singer A, Adoro S, Park JH. 2008. Lineage fate and intense debate: myths, models and mechanisms of CD4- versus CD8-lineage choice. Nat Rev Immunol 8:788801.[PubMed]
108. Klein L, Kyewski B, Allen PM, Hogquist KA. 2014. Positive and negative selection of the T cell repertoire: what thymocytes see (and don't see). Nat Rev Immunol 14:377391.[PubMed]
109. Zumer K, Saksela K, Peterlin BM. 2013. The mechanism of tissue-restricted antigen gene expression by AIRE. J Immunol 190:24792482.[PubMed]
110. Coutinho A, Caramalho I, Seixas E, Demengeot J. 2005. Thymic commitment of regulatory T cells is a pathway of TCR-dependent selection that isolates repertoires undergoing positive or negative selection. Curr Top Microbiol Immunol 293:4371.[PubMed]
111. Jenkins MK, Khoruts A, Ingulli E, Mueller DL, McSorley SJ, Reinhardt RL, Itano A, Pape KA. 2001. In vivo activation of antigen-specific CD4 T cells. Annu Rev Immunol 19:2345.[PubMed]
112. Tanabe M, Karaki S, Takiguchi M, Nakauchi H. 1992. Antigen recognition by the T cell receptor is enhanced by CD8 alpha-chain binding to the alpha 3 domain of MHC class I molecules, not by signaling via the cytoplasmic domain of CD8 alpha. Int Immunol 4:147152.[PubMed]
113. González-Galarza FF, Takeshita LY, Santos EJ, Kempson F, Maia MH, da Silva AL, Teles e Silva AL, Ghattaoraya GS, Alfirevic A, Jones AR, Middleton D. 2015. Allele frequency net 2015 update: new features for HLA epitopes, KIR and disease and HLA adverse drug reaction associations. Nucleic Acids Res 43(D1):D784D788.[PubMed]
114. Jørgensen PB, Livbjerg AH, Hansen HJ, Petersen T, Höllsberg P. 2012. Epstein-Barr virus peptide presented by HLA-E is predominantly recognized by CD8(bright) cells in multiple sclerosis patients. PLoS One 7:e46120.[PubMed]
115. Pietra G, Romagnani C, Mazzarino P, Falco M, Millo E, Moretta A, Moretta L, Mingari MC. 2003. HLA-E-restricted recognition of cytomegalovirus-derived peptides by human CD8+ cytolytic T lymphocytes. Proc Natl Acad Sci USA 100:1089610901.[PubMed]
116. Hansen SG, Sacha JB, Hughes CM, Ford JC, Burwitz BJ, Scholz I, Gilbride RM, Lewis MS, Gilliam AN, Ventura AB, Malouli D, Xu G, Richards R, Whizin N, Reed JS, Hammond KB, Fischer M, Turner JM, Legasse AW, Axthelm MK, Edlefsen PT, Nelson JA, Lifson JD, Früh K, Picker LJ. 2013. Cytomegalovirus vectors violate CD8+ T cell epitope recognition paradigms. Science 340:1237874.[PubMed]
117. Shastri N, Cardinaud S, Schwab SR, Serwold T, Kunisawa J. 2005. All the peptides that fit: the beginning, the middle, and the end of the MHC class I antigen-processing pathway. Immunol Rev 207:3141.[PubMed]
118. Boutwell CL, Carlson JM, Lin TH, Seese A, Power KA, Peng J, Tang Y, Brumme ZL, Heckerman D, Schneidewind A, Allen TM. 2013. Frequent and variable cytotoxic-T-lymphocyte escape-associated fitness costs in the human immunodeficiency virus type 1 subtype B Gag proteins. J Virol 87:39523965.[PubMed]
119. Neumann-Haefelin C, Oniangue-Ndza C, Kuntzen T, Schmidt J, Nitschke K, Sidney J, Caillet-Saguy C, Binder M, Kersting N, Kemper MW, Power KA, Ingber S, Reyor LL, Hills-Evans K, Kim AY, Lauer GM, Lohmann V, Sette A, Henn MR, Bressanelli S, Thimme R, Allen TM. 2011. Human leukocyte antigen B27 selects for rare escape mutations that significantly impair hepatitis C virus replication and require compensatory mutations. Hepatology 54:11571166.[PubMed]
120. Fellay J, Shianna KV, Ge D, Colombo S, Ledergerber B, Weale M, Zhang K, Gumbs C, Castagna A, Cossarizza A, Cozzi-Lepri A, De Luca A, Easterbrook P, Francioli P, Mallal S, Martinez-Picado J, Miro JM, Obel N, Smith JP, Wyniger J, Descombes P, Antonarakis SE, Letvin NL, McMichael AJ, Haynes BF, Telenti A, Goldstein DB. 2007. A whole-genome association study of major determinants for host control of HIV-1. Science 317:944947.[PubMed]
121. Carrington M, Nelson GW, Martin MP, Kissner T, Vlahov D, Goedert JJ, Kaslow R, Buchbinder S, Hoots K, O'Brien SJ. 1999. HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage. Science 283:17481752.[PubMed]
122. Yewdell JW, Nicchitta CV. 2006. The DRiP hypothesis decennial: support, controversy, refinement and extension. Trends Immunol 27:368373.[PubMed]
123. Dolan BP, Bennink JR, Yewdell JW. 2011. Translating DRiPs: progress in understanding viral and cellular sources of MHC class I peptide ligands. Cell Mol Life Sci 68:14811489.[PubMed]
124. Goldberg AL, Cascio P, Saric T, Rock KL. 2002. The importance of the proteasome and subsequent proteolytic steps in the generation of antigenic peptides. Mol Immunol 39:147164.[PubMed]
125. Schubert U, Antón LC, Gibbs J, Norbury CC, Yewdell JW, Bennink JR. 2000. Rapid degradation of a large fraction of newly synthesized proteins by proteasomes. Nature 404:770774.[PubMed]
126. Saric T, Chang SC, Hattori A, York IA, Markant S, Rock KL, Tsujimoto M, Goldberg AL. 2002. An IFN-gamma-induced aminopeptidase in the ER, ERAP1, trims precursors to MHC class I-presented peptides. Nat Immunol 3:11691176.[PubMed]
127. Saveanu L, Carroll O, Lindo V, Del Val M, Lopez D, Lepelletier Y, Greer F, Schomburg L, Fruci D, Niedermann G, van Endert PM. 2005. Concerted peptide trimming by human ERAP1 and ERAP2 aminopeptidase complexes in the endoplasmic reticulum. Nat Immunol 6:689697.[PubMed]
128. Williams A, Peh CA, Elliott T. 2002. The cell biology of MHC class I antigen presentation. Tissue Antigens 59:317.[PubMed]
129. Lennon-Duménil AM, Bakker AH, Wolf-Bryant P, Ploegh HL, Lagaudrière-Gesbert C. 2002. A closer look at proteolysis and MHC-class-II-restricted antigen presentation. Curr Opin Immunol 14:1521.[PubMed]
130. Hiltbold EM, Roche PA. 2002. Trafficking of MHC class II molecules in the late secretory pathway. Curr Opin Immunol 14:3035.[PubMed]
131. Pathak SS, Lich JD, Blum JS. 2001. Cutting edge: editing of recycling class II:peptide complexes by HLA-DM. J Immunol 167:632635.[PubMed]
132. Schmid D, Münz C. 2007. Innate and adaptive immunity through autophagy. Immunity 27:1121.[PubMed]
133. Levine B, Deretic V. 2007. Unveiling the roles of autophagy in innate and adaptive immunity. Nat Rev Immunol 7:767777.[PubMed]
134. Ackerman AL, Cresswell P. 2004. Cellular mechanisms governing cross-presentation of exogenous antigens. Nat Immunol 5:678684.[PubMed]
135. Heller KN, Gurer C, Münz C. 2006. Virus-specific CD4+ T cells: ready for direct attack. J Exp Med 203:805808.[PubMed]
136. Soghoian DZ, Jessen H, Flanders M, Sierra-Davidson K, Cutler S, Pertel T, Ranasinghe S, Lindqvist M, Davis I, Lane K, Rychert J, Rosenberg ES, Piechocka-Trocha A, Brass AL, Brenchley JM, Walker BD, Streeck H. 2012. HIV-specific cytolytic CD4 T cell responses during acute HIV infection predict disease outcome. Sci Transl Med 4:123ra25.[PubMed]
137. Lilley BN, Ploegh HL. 2005. Viral modulation of antigen presentation: manipulation of cellular targets in the ER and beyond. Immunol Rev 207:126144.[PubMed]
138. Noriega V, Redmann V, Gardner T, Tortorella D. 2012. Diverse immune evasion strategies by human cytomegalovirus. Immunol Res 54:140151.[PubMed]
139. Hansen TH, Bouvier M. 2009. MHC class I antigen presentation: learning from viral evasion strategies. Nat Rev Immunol 9:503513.[PubMed]
140. Davis MM, Bjorkman PJ. 1988. T-cell antigen receptor genes and T-cell recognition. Nature 334:395402.[PubMed]
141. Dustin ML. 2003. Coordination of T cell activation and migration through formation of the immunological synapse. Ann NY Acad Sci 987:5159.[PubMed]
142. Acuto O, Michel F. 2003. CD28-mediated co-stimulation: a quantitative support for TCR signalling. Nat Rev Immunol 3:939951.[PubMed]
143. Wang S, Zhu G, Chapoval AI, Dong H, Tamada K, Ni J, Chen L. 2000. Costimulation of T cells by B7-H2, a B7-like molecule that binds ICOS. Blood 96:28082813.[PubMed]
144. Schwartz RH. 2003. T cell anergy. Ann Rev Immunol 21:305334.[PubMed]
145. Weninger W, Manjunath N, von Andrian UH. 2002. Migration and differentiation of CD8+ T cells. Immunol Rev 186:221233.[PubMed]
146. Pearce EL, Mullen AC, Martins GA, Krawczyk CM, Hutchins AS, Zediak VP, Banica M, DiCioccio CB, Gross DA, Mao CA, Shen H, Cereb N, Yang SY, Lindsten T, Rossant J, Hunter CA, Reiner SL. 2003. Control of effector CD8+ T cell function by the transcription factor Eomesodermin. Science 302:10411043.[PubMed]
147. Sullivan BM, Juedes A, Szabo SJ, von Herrath M, Glimcher LH. 2003. Antigen-driven effector CD8 T cell function regulated by T-bet. Proc Natl Acad Sci USA 100:1581815823.[PubMed]
148. Kallies A, Xin A, Belz GT, Nutt SL. 2009. Blimp-1 transcription factor is required for the differentiation of effector CD8(+) T cells and memory responses. Immunity 31:283295.[PubMed]
149. Potter TA, Grebe K, Freiberg B, Kupfer A. 2001. Formation of supramolecular activation clusters on fresh ex vivo CD8+ T cells after engagement of the T cell antigen receptor and CD8 by antigen-presenting cells. Proc Natl Acad Sci USA 98:1262412629.[PubMed]
150. Russell JH, Ley TJ. 2002. Lymphocyte-mediated cytotoxicity. Annu Rev Immunol 20:323370.[PubMed]
151. Hu Z, Zhang W, Usherwood EJ. 2013. Regulatory CD8+ T cells associated with erosion of immune surveillance in persistent virus infection suppress in vitro and have a reversible proliferative defect. J Immunol 191:312322.[PubMed]
152. Billerbeck E, Thimme R. 2008. CD8+ regulatory T cells in persistent human viral infections. Hum Immunol 69:771775.[PubMed]
153. Sun JC, Williams MA, Bevan MJ. 2004. CD4+ T cells are required for the maintenance, not programming, of memory CD8+ T cells after acute infection. Nat Immunol 5:927933.[PubMed]
154. Intlekofer AM, Takemoto N, Kao C, Banerjee A, Schambach F, Northrop JK, Shen H, Wherry EJ, Reiner SL. 2007. Requirement for T-bet in the aberrant differentiation of unhelped memory CD8+ T cells. J Exp Med 204:20152021.[PubMed]
155. Wherry EJ. 2011. T cell exhaustion. Nat Immunol 12:492499.[PubMed]
156. Castellino F, Germain RN. 2007. Chemokine-guided CD4+ T cell help enhances generation of IL-6RalphahighIL-7Ralpha high prememory CD8+ T cells. J Immunol 178:778787.[PubMed]
157. Ahmed KA, Wang L, Munegowda MA, Mulligan SJ, Gordon JR, Griebel P, Xiang J. 2012. Direct in vivo evidence of CD4+ T cell requirement for CTL response and memory via pMHC-I targeting and CD40L signaling. J Leukoc Biol 92:289300.[PubMed]
158. Nakanishi Y, Lu B, Gerard C, Iwasaki A. 2009. CD8(+) T lymphocyte mobilization to virus-infected tissue requires CD4(+) T-cell help. Nature 462:510513.[PubMed]
159. Yi JS, Du M, Zajac AJ. 2009. A vital role for interleukin-21 in the control of a chronic viral infection. Science 324:15721576.[PubMed]
160. Elsaesser H, Sauer K, Brooks DG. 2009. IL-21 is required to control chronic viral infection. Science 324:15691572.[PubMed]
161. Chevalier MF, Jülg B, Pyo A, Flanders M, Ranasinghe S, Soghoian DZ, Kwon DS, Rychert J, Lian J, Muller MI, Cutler S, McAndrew E, Jessen H, Pereyra F, Rosenberg ES, Altfeld M, Walker BD, Streeck H. 2011. HIV-1-specific interleukin-21+ CD4+ T cell responses contribute to durable viral control through the modulation of HIV-specific CD8+ T cell function. J Virol 85:733741.[PubMed]
162. Feng G, Zhang JY, Zeng QL, Jin L, Fu J, Yang B, Sun Y, Jiang T, Xu X, Zhang Z, Yuan J, Wu L, Wang FS. 2013. HCV-specific interleukin-21+CD4+ T cells responses associated with viral control through the modulation of HCV-specific CD8+ T cells function in chronic hepatitis C patients. Mol Cells